James Condulis
Stock Analyst at Stifel
(1.20)
# 3,686
Out of 5,172 analysts
11
Total ratings
44.44%
Success rate
-4.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $21 | $13.81 | +52.06% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Hold | $24 → $6 | $4.07 | +47.42% | 2 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $28.94 | +72.77% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $4.28 | +133.64% | 1 | Dec 5, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $61.70 | +55.59% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $33.22 | +225.11% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $29.06 | +3.23% | 1 | Jan 22, 2025 |
Amylyx Pharmaceuticals
Mar 3, 2026
Initiates: Buy
Price Target: $21
Current: $13.81
Upside: +52.06%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Hold
Price Target: $24 → $6
Current: $4.07
Upside: +47.42%
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $28.94
Upside: +72.77%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $4.28
Upside: +133.64%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $61.70
Upside: +55.59%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $33.22
Upside: +225.11%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $29.06
Upside: +3.23%